What Emergence Therapeutics does

Emergence Therapeutics is a privately held, clinical-stage biopharmaceutical company headquartered in Duisburg, Germany, founded in 2019. The company is developing novel antibody-drug conjugate (ADC) immunotherapies for cancers with high unmet need, with its lead program directed at a recently validated oncology target. Management is positioning this lead ADC as potentially superior to Padcev (enfortumab vedotin), an established ADC approved for urothelial carcinoma, on the basis of differentiated target biology and ADC design rather than first-in-class mechanism.

The business is built around a proprietary ADC platform that combines target selection against a clinically validated receptor with conjugate chemistry intended to improve efficacy and/or safety relative to approved ADCs in the same class. The team is small (stated 1–10 employees) and led in the clinic by Chief Medical Officer Hatem Azim; no broader management team, board composition, or operational footprint is disclosed in the input.

As a pre-revenue private biotech, Emergence Therapeutics generates no product revenue today and has not disclosed pricing, licensing income, or partnership economics. Its financial foundation is the approximately $98.1 million Series A financing closed in December 2021, led by Pontifax with participation from a broad transatlantic syndicate including OrbiMed, RA Capital Management, Surveyor Capital, Kurma Partners, Bpifrance, Hadean Ventures, HTGF, NRW.BANK, and Gruenderfonds Ruhr. Capital from this round is being deployed to advance the lead ADC through preclinical and early clinical development, with the strategic intent of extending into adjacent oncology indications served by the same target biology.

Name

Emergence Therapeutics

Legal name

Emergence Therapeutics

Website

https://emergencetx.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Emergence Therapeutics is a privately held German biopharmaceutical company developing novel antibody-drug conjugate (ADC) immunotherapies for cancers with high unmet need, with its lead program positioned against a recently validated oncology target as a potential improvement over Padcev.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals (ADC Therapeutics)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industries

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Antibody-drug conjugates
• Oncology therapeutics
• ADC immunotherapy
• Cancer drug development
• Biopharmaceutical products

Headquarters

HQ city

Duisburg

HQ country

Germany

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Emergence Therapeutics develops antibody-drug conjugate (ADC) immunotherapies targeting cancers with high unmet medical need. Its lead ADC program is directed against a recently validated oncology target and is positioned as potentially superior to the approved ADC Padcev (enfortumab vedotin). The company focuses on next-generation ADC design combining targeted antibodies with cytotoxic payloads for selective tumor cell killing.

Product overview

Eli Lilly and Company is a global pharmaceutical company offering a portfolio of patented medications across multiple therapeutic areas. The company's direct-to-consumer offerings include LillyDirect (a pharmacy and home delivery service), a clinical trial enrollment platform for patient participation, and condition-specific information portals covering Alzheimer's disease, cancer, dermatology, autoimmune conditions, sleep apnea, diabetes, obesity, and migraine. The company has been developing medicines for 150 years with over 100 patented medications and 10 Prix Galien Awards.

Differentiator

Problem solved

Functional benefit

Products and services

• Lead ADC Program (anti-receptor ADC targeting a recently validated oncology target)

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves3 records

Expansion highlights4 records

Direct peers

• Heidelberg Pharma: German ADC developer using proprietary amanitin-based payload technology; partnered with Takeda. Most direct geographic and technology peer — both European preclinical/early-clinical ADC platform companies.
• ImmunoGen: ADC-focused biotech now part of AbbVie, with approved Elahere and a pipeline of additional ADC candidates. Highly comparable business model as a pure-play ADC developer.
• Pyxis Oncology: Clinical-stage ADC biotech developing next-generation antibody-drug conjugates using novel linker chemistry and tumor-activated payloads. Comparable stage, size, and ADC-platform strategy to Emergence.
• Mersana Therapeutics: Clinical-stage biotech developing next-generation ADCs using proprietary platforms (Dolasynthen, Immunosynthen). Closely comparable size, stage, and ADC-platform strategy.
• Seagen: Pioneer in ADC technology (Adcetris, Padcev co-development) and now part of Pfizer. Closely comparable technology focus and validated the ADC business model that Emergence is pursuing.
• Tubulis: German ADC biotech with proprietary linker and payload technologies, raised large Series A2/B rounds from European and US investors. Closely comparable in geography, stage, and technology approach.
• Astellas Pharma: Developer of Padcev (enfortumab vedotin) in partnership with Pfizer — the very approved ADC Emergence is positioning its lead program against. Direct comparator for clinical, regulatory, and commercial benchmarking in urothelial carcinoma.

Broad incumbents

• Pfizer: Co-developer of Padcev with Astellas and acquirer of Seagen ($43B, 2023), making it the dominant force in the ADC space. Competes for the same urothelial carcinoma market and is a likely strategic acquirer or partner for ADC innovators.
• Daiichi Sankyo: Global ADC leader behind Enhertu (with AstraZeneca) and Datroway, with the largest ADC pipeline in oncology. Sets the benchmark for ADC linker/payload chemistry and commercial execution.

Emerging players

• Bolt Biotherapeutics: Clinical-stage biotech developing immune-stimulating antibody conjugates (ISACs), an ADC-adjacent modality. Comparable size and stage, with overlapping payload-conjugate approach and oncology focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emergence Therapeutics